undefined undefined undefined

Integrating point-of-care NT-proBNP testing into mobile health: enhancing diagnosis, screening, and monitoring of heart failure

Event: ESC Digital & AI Summit 2025

Topic: m-Health & Mobile Apps

Session: Evaluating the clinical impact of mHealth solutions in cardiology

Access

Like

CA125 assessment using ABEI-based assay in heart failure: implications for disease severity and cardiac biomarkers

Event: Heart Failure 2024

Topic: Biomarkers

Session: ePosters in chronic heart failure - biomarkers 1

Access

Like

Increase of CA125 in Heart Failure with reduced ejection fraction: association with cardiovascular mortality, Galectin-3 and Fibroblast Growth Factor-23

Event: Heart Failure 2022

Topic: Biomarkers

Session: Heart Failure ePosters - focus on Chronic Heart Failure 2

Access

Like

The ratio of fibroblast growth factor 23 to phosphorus as a predictor of cardiovascular death in heart failure patients with reduced ejection fraction.

Event: Heart Failure 2019

Topic: Biomarkers

Session: Chronic Heart Failure – Diagnostic Methods

Access

Like

Determinant factors of plasma fibroblast growth factor 23 levels in patients with heart failure patients with reduced ejection fraction

Event: Heart Failure 2019

Topic: Biomarkers

Session: Chronic Heart Failure – Diagnostic Methods

Access

Like

Increase of high molecular weight adiponectin in heart failure patients with reduced ejection fraction.

Event: Heart Failure 2018

Topic: Biomarkers

Session: Chronic Heart Failure – Diagnostic Methods

Access

Like

Incremental value of intact fibroblast Growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patientsg

Event: Heart Failure 2018

Topic: Biomarkers

Session: Chronic Heart Failure – Diagnostic Methods

Access

Like

Assessment of intact fibroblast growth factor 23 in patients with heart failure with reduced ejection fraction

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Hormones / neurohumoral regulation

Session: Hormones - Neurohumoral regulation

Access

Like

Combining natriuretic peptides and 1, 25-dihydroxyvitamin D testing improves the predictive value for cardiovascular death in heart failure

Event: HEART FAILURE 2016

Topic: Natriuretic peptides

Session: Biomarkers

Access

Like

Testing for soluble ST2 in heart failure patients: reliability of a point of care method

Event: HEART FAILURE 2016

Topic: Inflammation

Session: Biomarkers

Access

Like

undefined undefined undefined

Contributor content

Integrating point-of-care NT-proBNP testing into mobile health: enhancing diagnosis, screening, and monitoring of heart failure

CA125 assessment using ABEI-based assay in heart failure: implications for disease severity and cardiac biomarkers

Increase of CA125 in Heart Failure with reduced ejection fraction: association with cardiovascular mortality, Galectin-3 and Fibroblast Growth Factor-23

The ratio of fibroblast growth factor 23 to phosphorus as a predictor of cardiovascular death in heart failure patients with reduced ejection fraction.

Determinant factors of plasma fibroblast growth factor 23 levels in patients with heart failure patients with reduced ejection fraction

Increase of high molecular weight adiponectin in heart failure patients with reduced ejection fraction.

Incremental value of intact fibroblast Growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patientsg

Assessment of intact fibroblast growth factor 23 in patients with heart failure with reduced ejection fraction

Combining natriuretic peptides and 1, 25-dihydroxyvitamin D testing improves the predictive value for cardiovascular death in heart failure

Testing for soluble ST2 in heart failure patients: reliability of a point of care method

ESC 365 is supported by